(AOF) – The expected drop in sales of Covid tests, associated with the low level of winter pathologies at the end of the year, should lead to a decline in the Boiron group’s turnover as well as a slight drop in operating income in 2023 compared to 2022, before other operating income and expenses. This is what the homeopathy specialist announced following its Board of Directors meeting on December 19, 2023.
Representatives of Boiron Developpement, the group’s majority shareholder, confirmed their intention, following the Simplified Public Purchase Offer (OPAS) whose timetable will be determined by the Financial Markets Authority (AMF), to implement a withdrawal of Boiron shares from the stock market “if the conditions are met”. In 2024, the group will only publish its annual and half-yearly results.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.